Figure 2. Circulating Immune Cell Populations.
Circulating immune cell populations at baseline prior to defect creation, and at Week 0 prior to BMP-2 treatment (8 weeks post-defect creation) for the bone only defect group and the composite defect group. Significance was determined using one-way ANOVA with p<0.01 (**), p<0.005 (***), and p<0.001 (****).